Chengdu Easton Biopharmaceuticals Adjusts Valuation Amid Modest Long-Term Growth Trends

Chengdu Easton Biopharmaceuticals Co., Ltd., a midcap player in the Pharmaceuticals & Biotechnology sector, has recently undergone an adjustment in its evaluation. This revision reflects a shift in the stock's valuation grade, moving from a previously attractive status to a fair assessment. Key financial metrics indicate that the company has a P/E ratio of 44 and a Price to Book Value of 3.54. The EV to EBIT stands at 50.01, while the EV to EBITDA is recorded at 36.78. Additionally, the company boasts a dividend yield of 0.51% and a return on equity (ROE) of 7.95%. Despite a positive financial performance in the quarter ending September 2025, long-term growth has been modest, with net sales increasing at an annual rate of 8.13% and operating profit at 7.15% over the past five years. The stock has generated a return of 79.71% over the last year, although profits have seen a decline of 4.7%. Overall, the adjustment in evaluation reflects the company's current market position and performance indicators. Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.